NeuroVasc Technologies brings over 100 years of combined expertise in neurovascular device design and development. We are committed to being the most dynamic creator of neurovascular devices in the world.
With a focus on novel catheter-based technologies to treat neurovascular disease, NeuroVasc has developed a portfolio strategy to bring differentiated tools to facilitate broad treatment options for patients suffering stroke and other neurovascular diseases.
ENVOKE™ has CE Mark.
ENVOKE™ is pending FDA Clearance, Not Available for Sale in the United States.
Stroke is the leading cause of serious long-term disability in the USA, and the 2nd leading cause of death worldwide8,9. According to AHA statistics, there are about 795,000 new strokes per in the USA alone resulting in 146,383 deaths8.
Your message has been received and we'll be in touch soon!
CE marked product information
The ENVI™-SR is intended for use to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV tPA or who fail IV tPA therapy are candidates for treatment.
Use of the ENVI™-SR is contraindicated under these circumstances:
Possible complications of the use of the ENVI™-SR include, but are not limited to:
CE marked product information
The ENVOKE™ catheters are intended for the introduction of interventional devices and infusion of diagnostic or therapeutic agents into the neuro, peripheral, and coronary vasculatures.
None known
Possible complications of the use of the ENVOKE™ catheter include, but are not limited to: